Brief debrisoquin administration to assess central dopaminergic function in children.

[1]  C. Bowden,et al.  Effects of debrisoquin on CSF and plasma HVA concentrations in man. , 1985, Life sciences.

[2]  D. Cohen,et al.  1703 PLASMA MONOAMINE METABOLITES FOLLOWING DEBRISOQUIN IN ADD , 1985, Pediatric Research.

[3]  K. Davis,et al.  Plasma homovanillic acid concentration and the severity of schizophrenic illness. , 1985, Science.

[4]  D. Hommer,et al.  Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. , 1984, Science.

[5]  M. Friedman,et al.  Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics. , 1984, Biological psychiatry.

[6]  P. Jatlow,et al.  Plasma catecholamine metabolites and early response to haloperidol. , 1984, The Journal of clinical psychiatry.

[7]  A. Panerai,et al.  Methionine enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patients , 1984, Neurology.

[8]  J. Bartko,et al.  Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients. , 1983, Archives of general psychiatry.

[9]  G. Heninger,et al.  Tardive dyskinesia and plasma homovanillic acid. , 1983, Biological psychiatry.

[10]  R. Roth,et al.  Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin. , 1983, Life sciences.

[11]  J. Idle,et al.  Genetically determined oxidation capacity and the disposition of debrisoquine. , 1983, British journal of clinical pharmacology.

[12]  K. Davis,et al.  The effects of diet and physical activity on plasma homovanillic acid in normal human subjects , 1983, Psychiatry Research.

[13]  S. Snyder,et al.  Neurotransmitters and CNS disease. Schizophrenia. , 1982, Lancet.

[14]  J. Coyle,et al.  Dopaminergic dysfunction in tourette syndrome , 1982 .

[15]  R. Roth,et al.  Influence of dopamine agonists on plasma and brain levels of homovanillic acid. , 1982, Life sciences.

[16]  D. Jeste,et al.  Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients. , 1982, Life sciences.

[17]  M. Åsberg,et al.  Monoamine metabolites in CSF and suicidal behavior. , 1981, Archives of general psychiatry.

[18]  R. Roth,et al.  Brain contribution to the haloperidol-induced increase in plasma homovanillic acid. , 1981, European journal of pharmacology.

[19]  H. Landis,et al.  Catecholamine metabolites in human plasma as indices of brain function: effects of debrisoquin. , 1980, Life sciences.

[20]  N. M. Greene,et al.  Estimates of Dopamine and Serotonin Synthesis by the Awake Human Brain , 1980, Journal of neurochemistry.

[21]  J. Maas,et al.  Differential effects on brain catecholamines by debrisoquin. , 1979, Biochemical pharmacology.

[22]  R. Caprioli,et al.  Biogenic amine metabolism in tourette syndrome , 1979, Annals of neurology.

[23]  R. Roth,et al.  3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. , 1979, European journal of pharmacology.

[24]  J. Nathanson,et al.  Central biogenic amine metabolism in children with the syndrome of chronic multiple tics of Gilles de la Tourette: norepinephrine, serotonin, and dopamine. , 1979, Journal of the American Academy of Child Psychiatry.

[25]  J. Maas,et al.  A DIRECT METHOD FOR DETERMINING DOPAMINE SYNTHESIS AND OUTPUT OF DOPAMINE METABOLITES FROM BRAIN IN AWAKE ANIMALS , 1979, Journal of neurochemistry.

[26]  R. Roth,et al.  A direct method for studying 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) production by brain in awake animals. , 1977, European journal of pharmacology.

[27]  S. Young,et al.  Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies. , 1974, Brain research.

[28]  R. Wyatt,et al.  Estimation of the contribution of peripheral and central noradrenergic neurones to urinary 3-methoxy-4-hydroxyphenylglycol in the rat. , 1974, Neuropharmacology.

[29]  R. Wurtman,et al.  EFFECT OF SELECTIVE DESTRUCTION OF CENTRAL AND PERIPHERAL CATECHOLAMINE‐CONTAINING NEURONES WITH 6‐HYDROXYDOPAMINE ON CATECHOLAMINE EXCRETION IN THE RAT , 1974, British journal of pharmacology.

[30]  P. A. Shore,et al.  On the physiological disposition and possible mechanism of the antihypertensive action of debrisoquin. , 1969, Biochemical pharmacology.

[31]  H. M. Solomon,et al.  The influence of debrisoquin on the accumulation and metabolism of biogenic amines by the human platelet, in vivo and in vitro , 1969, Clinical pharmacology and therapeutics.

[32]  R. Pocelinko,et al.  CLINICAL PHARMACOLOGICAL STUDIES WITH DEBRISOQUIN SULFATE, A NEW ANTIHYPERTENSIVE AGENT. , 1964, The Journal of new drugs.